Management of Bladder Cancer. a Comprehensive Text with Clinical Scenarios

Description

Management of bladder cancer provides a single, comprehensive reference source that incorporates all the latest information regarding bladder cancer. The text covers epidemiology and natural history of bladder cancer as well as latest findings regarding the genetics and molecular biology of the disease. Diagnostic and staging evaluation of both non-muscle invasive and invasive bladder cancer is discussed. The text incorporates chapters summarizing new findings regarding markers for the diagnosis of bladder cancer and new diagnostic techniques to enhance traditional methods such as cystoscopy. Risk stratified treatment of non muscle invasive bladder cancer including various approaches to intravesical therapy are reviewed. Current guideline based approaches to management and new data regarding diagnosis and prognostication of muscle invasive bladder cancer is analyzed and summarized. The application of chemotherapy for muscle invasive and advanced disease is discussed and the evidence based application of multimodality therapy highlighted. Finally, gaps in current knowledge and areas for future research are highlighted. Ongoing important clinical trials which could imminently yield significant new knowledge is discussed.

Authored by experts in their respective fields, Management of Bladder Cancer will serve as a easy and complete reference source for clinicians, researchers, individuals in training, allied health professionals and medical students in the fields of Urology, Medical Oncology, Radiation Oncology, Basic and Translational Science and Epidemiology.

Feature

• Authored by experts in their respective fields
• Provides a single, comprehensive reference source
• Useful resource for phy

Table of Contents

I. GENERAL CONCEPTS

1. Epidemiology and natural history
Edward Messing and Emil Scosyrev

2. Screening for Bladder Cancer
Laura-Maria Krabbe, Robert S. Svatek and Yair Lotan

3. Pathology and Staging: Histopathology and Cytopathology
Amber Mackey, Farnaz Hasteh and Donna E. Hansel

4. Pathology and Staging: Genetics and Molecular Biology
Sean McAdams and Michael C. Risk

5. Imaging in Localized and Advanced Bladder Cancer
Timothy Kim, Joshua G. Griffin, Jeffrey M. Holzbeierlein and Wade J. Sexton

6. New Imaging Techniques in Staging of Urothelial Carcinoma of the Bladder
Ramdev Konijeti and Adam S. Kibel

7. Socioeconomic issues and improved quality of care
John L. Gore

8. Quality of life measures
Christopher B. Anderson, David F. Penson and Daniel A. Barocas

9. Prognostication and risk assessment
Luis Alex Kluth, Bernie Bochner and Shahrokh F. Shariat

10. Clinical trials and emerging therapeutic strategies in bladder cancer
Richard M. Bambury, Robert B. Sims and Jonathan E. Rosenberg

II. NON MUSCLE INVASIVE BLADDER CANCER

11. Improved diagnostic techniques
Seth P. Lerner and Alvin C. Goh

12. Clinical scenario: Microscopic hematuria and atypical cytology in a 68 year old man with normal upper tract imaging
Christopher S. Gomez, Mark S. Soloway, Jorge Caso, Claudia P. Rojas and Merce Jorda

13. Localized surgical therapy and surveillance
Manish I. Patel and Paul D. Sved

14. Clinical Scenario: Initial high grade Ta tumor
Jose L. Dominguez-Escrig and Eduardo Solsona Narbón

15. Clinical Scenario: Recurrent Ta tumor
Joseph A. Gillespie and Michael A. O'Donnell

16. Clinical Scenario: Rapidly growing, high volume, low grade Ta tumor
James S. Rosoff and Thomas A. Keane

17. Clinical Scenario: Low grade T1 tumor
J. Alfred Witjes and Florine W.M. Schlatmann

18. Intravesical therapy
Jennifer J. Ahn and James M. McKiernan

19. Clinical Scenario: Initial CIS
Sima P. Porten and Colin P. Dinney

20. Management of BCG Recurrent Bladder Cancer
Tracy M. Downs, Daniel J. Lee and Douglass S. Scherr

21. Clinical Scenario: Persistent CIS and HIGH Grade Ta Bladder Cancer after BCG
Maurizio Brausi

22. Clinical Scenario: Presentation and Management of Significant Side Effects from Bacillus Calmette-Guérin Bladder Instillation
Donald L. Lamm and Nilay M. Gandhi

23. Guideline-based management of non-muscle invasive bladder cancer: comparison of the AUA, EAU, ICUD and NCCN guidelines
Jeffrey C. Bassett, John D. Seigne and Peter E. Clark

III. MUSCLE INVASIVE BLADDER CANCER

24. Open Radical Cystectomy
J. Joy Lee, Dipen J. Parekh and Mark L. Gonzalgo

25. Robotic cystectomy
Michael Woods, Raj Pruthi and Erik P. Castle

26. Clinical Scenario: T2 bladder tumor
Richard E. Hautmann

27. Urinary Diversion: Open and robotic techniques
Norm D. Smith, Gary D. Steinberg and Cheryl T. Lee

28. Chemoradiotherapy
Christian Weiss and Claus Rödel

29. Clinical Scenario: 53 year-old man with a solitary, 2 cm, high-grade T2 tumor and focal CIS in the bladder dome who wants bladder preservation
Albert J. Chang, Maurice Marcel Garcia and Mack Roach III

30. Management of Bladder Cancer, role of chemotherapy and controversies surrounding its application
Gautam Jha, Guru Sonpavde and Zeeshan Ahmad

31. Clinical Scenario: Large volume, non metastatic T2 bladder tumor
Chad R. Ritch and Michael S. Cookson

32. The role of pelvic lymphadenectomy at the time of radical cystectomy for bladder cancer
Samuel D. Kaffenberger, Todd M. Morgan and Anne K. Schuckman

33. Clinical Scenario: Unexpected positive nodes at radical cystectomy
Christian Thomas and Joachim W. Thüroff

34. Surveillance and monitoring
Daniel J. Canter, Joseph Zabell, Stephen A. Boorjian and Christopher J. Weight

35. Clinical Scenario: The Role of Perioperative Chemotherapy
Eila C. Skinner

36. Management of Bladder Cancer with Pelvic Nodal Metastases After Complete Response to Chemotherapy
Adam C. Reese and Mark P. Schoenberg

37. Guideline based management muscle-invasive bladder cancer: NCCN, ICUD and EAU
Amanda N. Calhoun and Kamal S. Pohar